CD19 CHO Recombinant Cell Line (Low, Medium and High Expression)

Only %1 left

Catalog #

79561

As low as $7,150 *

Cat # Size Price*

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Recombinant clonal stable CHO cell line constitutively expressing full length human CD19 protein, also known as B4 or CVID3, (Genbank #NM_001770). Surface expression of CD19 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD19 expression (High, Medium, Low) to mimic different stages of cancer target cells with various CD19 expression levels.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

●

Synonyms

B-lymphocyte surface antigen B4, Leu-12

●

Product Data Gallery

Expression of CD19 validated by flow cytometry

Product Info

Storage and Usage

Citations

Host Cell Line

CHO K1 cell line, Chinese Hamster Ovary

Supplied As

Each vial contains ~ 2 x 10⁶ cells in 1 ml of 10% DMSO in FBS.

UniProt #

P15391

Mycoplasma Testing

This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.

Background

B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells, except plasma cells. CD19 plays two major roles in human B cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development and lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies. CD19-targeted therapies based on T cells that express CD19-specific chimeric antigen receptors (CARs) have been utilized for their antitumor abilities in patients with CD19+ lymphoma and leukemia, such as Non-Hodgkins Lymphoma (NHL), CLL and ALL.

References

1. Tedder TF, et al. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J. Immunol. 1989 Jul 15;143(2):712

2. Kemeng W, et al. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Experimental Hematology & Oncology 2012 1:36

3. Michel S. CD19 CAR T Cells. Cell 2017 Dec 14; 171(7):1471

Storage/Stability

Store in liquid nitrogen immediately upon receipt.

Growth Media

For best results, it is highly recommended to use these validated and optimized media from BPS Bioscience. Other preparations or formulations of media may result in suboptimal performance.

Thaw Medium 3 (BPS Bioscience, #60186): F-12K Medium supplemented with 10% FBS, 1% Penicillin/Streptomycin

Growth Medium 3D (BPS Bioscience, #79539): F-12K Medium supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 1 mg/ml G418

Shipping Temperature

-80°C

Notes

License Disclosure
Visit bpsbioscience.com/license for the label license and other key information about this product.

Troubleshooting Guide
Visit bpsbioscience.com/cell-line-faq for detailed troubleshooting instructions. For all further questions, please email [email protected].

Warnings

Avoid freeze/thaw cycles

Scientific Category

Immunotherapy

Regulatory Status

Research Use Only